Scholarlink

Purpose <p>The main objective was to evaluate the hearing impairment of patients after hypofractionated stereotactic radiotherapy (HSRT) by CyberKnife<sup>®</sup> for vestibular schwannoma (VS).</p> Methods <p>Patients treated by HSRT with CyberKnife<sup>®</sup> for sporadic progressive VS between January 2010 and February 2020 with at least 1 year follow-up were included. Exclusion criteria were pre-treatment cophosis, lack of at least one pre- and post-irradiation hearing test, a history of treatment of the VS. Bilateral pure-tone testing and speech testing, magnetic resonance imaging (MRI) characteristics of the VS (volume, Koos classification, fundus and internal auditory canal invasion), and HSRT characteristics (80% isodose, number of fractions, dose per fraction, mean cochlear dose) were collected before HSRT and at 1, 3, and 5 years follow-up.</p> Results <p>71 patients with a 1-year follow-up were included, 55 patients had a 3-year follow-up, and 34 had a 5-year follow-up; the mean follow-up was 43 months (± 24). During the entire follow-up, 89% of the patients (63/71) had hearing impairment, which occurred during the first year for 79% (56/71) of the patients. No risk factor among age, MRI characteristics, and HSRT modalities were found to be associated with hearing impairment in the first year. No relationship was found between tumor volume and hearing impairment.</p> Conclusion <p>For most patients, HSRT is responsible for hearing impairment within the first year.</p> Trial registration number <p>#20–84 on September the 10th, 2021.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hearing outcome after Cyberknife® radiotherapy for vestibular Schwannoma

  • 期刊论文

  • 发表日期：

    2025年11月4日

查看全文
  • Manon Bachelet,
  • Romain Tournegros,
  • Maxime Fieux,
  • Ronan Tanguy,
  • Pierre-Marie Pialat,
  • Fabien Subtil,
  • Stéphane Tringali

摘要

Purpose

The main objective was to evaluate the hearing impairment of patients after hypofractionated stereotactic radiotherapy (HSRT) by CyberKnife® for vestibular schwannoma (VS).

Methods

Patients treated by HSRT with CyberKnife® for sporadic progressive VS between January 2010 and February 2020 with at least 1 year follow-up were included. Exclusion criteria were pre-treatment cophosis, lack of at least one pre- and post-irradiation hearing test, a history of treatment of the VS. Bilateral pure-tone testing and speech testing, magnetic resonance imaging (MRI) characteristics of the VS (volume, Koos classification, fundus and internal auditory canal invasion), and HSRT characteristics (80% isodose, number of fractions, dose per fraction, mean cochlear dose) were collected before HSRT and at 1, 3, and 5 years follow-up.

Results

71 patients with a 1-year follow-up were included, 55 patients had a 3-year follow-up, and 34 had a 5-year follow-up; the mean follow-up was 43 months (± 24). During the entire follow-up, 89% of the patients (63/71) had hearing impairment, which occurred during the first year for 79% (56/71) of the patients. No risk factor among age, MRI characteristics, and HSRT modalities were found to be associated with hearing impairment in the first year. No relationship was found between tumor volume and hearing impairment.

Conclusion

For most patients, HSRT is responsible for hearing impairment within the first year.

Trial registration number

#20–84 on September the 10th, 2021.